Hematological responses in patients in parts A and B
| Response . | Barasertib dose . | |||||||
|---|---|---|---|---|---|---|---|---|
| Part A . | Part B . | |||||||
| 50 mg (n = 3) . | 100 mg (n = 3) . | 200 mg (n = 3) . | 400 mg (n = 4) . | 800 mg (n = 7) . | 1200 mg (n = 6) . | 1600 mg (n = 6) . | 1200 mg (n = 32) . | |
| CR, n (%) | 0 | 0 | 0 | 0 | 0 | 1 (17) | 0 | 2 (6) |
| Cri, n (%) | 0 | 0 | 0 | 1 (25) | 1 (14) | 0 | 0 | 4 (13)* |
| PR, n (%) | 0 | 1 (33) | 0 | 0 | 1 (14) | 1 (17) | 2 (33) | 2 (6) |
| Response . | Barasertib dose . | |||||||
|---|---|---|---|---|---|---|---|---|
| Part A . | Part B . | |||||||
| 50 mg (n = 3) . | 100 mg (n = 3) . | 200 mg (n = 3) . | 400 mg (n = 4) . | 800 mg (n = 7) . | 1200 mg (n = 6) . | 1600 mg (n = 6) . | 1200 mg (n = 32) . | |
| CR, n (%) | 0 | 0 | 0 | 0 | 0 | 1 (17) | 0 | 2 (6) |
| Cri, n (%) | 0 | 0 | 0 | 1 (25) | 1 (14) | 0 | 0 | 4 (13)* |
| PR, n (%) | 0 | 1 (33) | 0 | 0 | 1 (14) | 1 (17) | 2 (33) | 2 (6) |
One patient in Part B was not transfusion independent at the time of CRi.